Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727) . Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3 [2]. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice .
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia [2] .
SD-36 is a potent and efficacious STAT3 PROTAC degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase . SD-36 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
STAT6-IN-1 (Compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [2] .
SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36 .
STAT6-IN-3 is a phosphopeptide mimic targeting the SH2 domain of STAT6 and has a high affinity for STAT6 (IC50: 0.04 μM). STAT6-IN-3 can be used in the research of inflammation such as asthma .
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .
ZAP-180013 is a zeta-chain-associated protein kinase 70 (ZAP-70) inhibitor with an IC50 of 1.8 μM. ZAP-180013 inhibits the interaction of ZAP-70SH2 domain with immunoreceptor tyrosine-based activation motif (ITAMs) .
5,15-Diphenylporphyrin (5,15-DPP) is an inhibitor of the oncogenic transcription factor STAT3. 5,15-Diphenylporphyrin specifically binds to the SH2 domain of STAT3, blocking the pTyr-SH2 interaction, thereby inhibiting the dimerization, nuclear translocation and DNA binding activity of STAT3, and ultimately inhibiting the expression of cancer cell-related genes. 5,15-Diphenylporphyrin can be used in research fields related to the development of anticancer drugs[1][2].
Erasin is a potent Erlotinib (HY-50896)-resistance antagonizing STAT3 inhibitor with IC50s of 9.7 and 24 μM against STAT3 and STAT1, respectively. Erasin induces cancer cells apoptosis .
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains [2].
C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC50 of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC50s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .
Grb2SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
Grb2SH2 domain inhibitor 1 is an inhibitor of the Grb2SH2 domain with an IC50 of 0.40 μM. Grb2SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2SH2 domain inhibitor 1 downregulates the expression level of p-MEK. Grb2SH2 domain inhibitor 1 can be used in the research of breast cancer .
STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
STAT3-IN-13 (compound 6f) is a potent STAT3 inhibitor. STAT3-IN-13 has anti-proliferative effects and binds to the STAT3 SH2 domain with a KD of 0.46 μM. STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705 and downstream target gene expression. STAT3-IN-13 induces apoptosis in vitro and suppresses the growth and metastasis of tumor in vivo. STAT3-IN-13 can be used for cancer research .
PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [1].
pYEEI is a phosphotyrosine-containing tetrapeptide binds to Src SH2 domain with the Kd of 100 nM and with the IC50 of 6.5 μM. pYEEI plays an important role in cancer research .
G7-18NATE TFA is a peptide inhibitor of Grb7. G7-18NATE TFA binds to the Grb7-SH2 domain with micromolar affinity (Kd = 18.1 μM). G7-18NATE TFA inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
STAT3-IN-25 (Compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 has the potential for pancreatic cancer research .
Isocryptotanshinone is a dual STAT3 and PTP1B (IC50 = 56.1 μM) inhibitor. Isocryptotanshinone inhibits STAT3 by binding to the STAT3 SH2 domain to block phosphorylation and nuclear translocation [1][2]. Isocryptotanshinone exerts its anti-proliferative effect via the induction of cell cycle arrest, apoptosis, and pro-death autophagy, through the regulation of STAT3, AKT/mTOR and MAPK signaling pathways. Isocryptotanshinone suppresses the xenograft gastric cancer (GC) tumor growth in BALB/c nude mice. Isocryptotanshinone can be used for cancer research, such as lung cancer, breast cancer and GC .
AP22161 is a potent and selective Src SH2 domain inhibitor with an IC50 of 0.24 µM. AP22161 exhibits >120-fold selectivity over Yes SH2 (IC50 = 29.38 µM) and ZAP SH2 (IC50 = 421.86 µM). AP22161 inhibits Src-dependent cellular activity and diminishes osteoclast resorptive activity. AP22161 can be used for osteoporosis research .
NSC 57148 is a selective Grb7 SH2 domain antagonist with an IC50 value of 1.1 μM. NSC 57148 reduces cancer cell proliferation and migration. NSC 57148 is promising for research of Grb7-overexpressing malignancies such as breast and pancreatic cancers .
STAT3-IN-32 is an orally active, selective STAT3SH2 domain inhibitor with a Kd of 21.3 nM, showing selectivity over STAT1/5. STAT3-IN-32 binds to the STAT3SH2 domain, blocks Tyr705 and Ser727 phosphorylation, abrogates nuclear transcription and mitochondrial oxidative phosphorylation functions. STAT3-IN-32 inhibits tumor growth in mouse pancreatic cancer xenograft models. STAT3-IN-32 can be used for the research of pancreatic cancer .
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
Stattic (Standard) is the analytical standard of Stattic. This product is intended for research and analytical applications. Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727) . Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3 [2]. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice .
STAT3-IN-49 (compound B16) is a potent and selective STAT3 inhibitor. STAT3-IN-49 binds to the SH2 domain of STAT3, thereby suppressing its phosphorylation and nuclear translocation. STAT3-IN-49 inhibits triple-negative breast cancer (TNBC) cell migration, invasion, and colony formation. STAT3-IN-49 inhibits tumor growth in an MDA-MB-231 xenograft mouse model. STAT3-IN-49 can be used for TNBC research .
AP22408 is a nonpeptide inhibitor against Src SH2 with an IC50 value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .
5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide and has STAT3 inhibitory activity. 5-FAM-GpYLPQTV-NH2 (TFA) can be used in cancer research .
STAT3-IN-46 is a selective and orally active inhibitor of signal transducer and activator of transcription 3 (STAT3) (KD = 323.3 nM). STAT3-IN-46 directly binds to the SH2 domain of the STAT3 and inhibits IL-6/JAK/STAT3 signaling pathway (IC50 = 0.87 μM) and downregulates c-Myc and Bcl-2 levels. STAT3-IN-46 can be used for the research of cancer, such as triple-negative breast cancer .
N-Acetyl-O-phosphono-Tyr-Glu dipentylamide (Ac-Tyr-Glu-N(n-C5H11)2), a dipeptide, is a pp60 c-srcSH2 domain inhibitor. N-Acetyl-O-phosphono-Tyr-Glu dipentylamide can be used for cancer research .
STAT3-IN-35 is a STAT3 inhibitor that binds to SH2 domain. STAT3-IN-35 inhibits the phosphorylation of STAT3 and possesses antiproliferative activities against triple-negative breast cancer (TNBC) cell lines. STAT3-IN-35 also has a toxicity and potent antitumor activity in a TNBC xenograft model .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions .
H2N-PEG1000-SH (Amine-PEG1000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG1000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
G7-18NATE is a peptide inhibitor of Grb7. HY-P10224 binds to the Grb7-SH2 domain with micromolar affinity (KD = 18.1 μM). G7-18NATE inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
STAT3-IN-38 (Compound 4m) is an inhibitor of STAT3 (KD of rhSTAT3: 45.33 µM). STAT3-IN-38 binds to the SH2 domain of STAT3 protein and suppresses the STAT3’s phosphorylation at site pTyr705 as well as its downstream genes (Survivin and Mcl-1). STAT3-IN-38 could block cell-cycle and induce Apoptosis in colorectal cancer cells .
Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research .
SH2B2 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2b3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sh2b3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2b3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sh2b3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B3 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2d1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sh2d1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2d1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Sh2d1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D2A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D4A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D3C Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D3C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1B Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
FITC-Acp-RpYTPEP-NH2 is a potent fluorescent tracer. FITC-Acp-RpYTPEP-NH2 shows a binding affinity (Kd = 0.07 μM) for the Cbl-bSH2 domain. Fluorescence polarization assay based on FITC-Acp-RpYTPEP-NH2 can be for evaluating Cbl-b SH2 domain inhibitors .
ODZ10117 is a STAT3 and NLRP3 inhibitor with a human STAT3 SH2 domain IC50 of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease [2] .
H2N-PEG10000-SH (Amine-PEG10000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG10000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG2000-SH (Amine-PEG2000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG2000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
YN11 is a STAT3 inhibitor (Kd=11.9 μM). YN11 directly binds to the SH2 domain of STAT3, inhibits the phosphorylation of STAT3, and reduces the expression of downstream target proteins. YN11 induces cell cycle arrest, promotes apoptosis, and inhibits cell invasion and migration in prostate cancer cells. YN11 suppresses tumor growth in a prostate cancer xenograft mouse model. YN11 does not cause significant body weight loss or obvious histopathological changes in major organs in xenograft mice. YN11 is applicable to relevant research on prostate cancer .
STAT3-IN-53 (Compound L20) is a STAT3 inhibitor with a Kd value of 6.16 μM. STAT3-IN-53 binds directly to the SH2 domain of STAT3, inhibits phosphorylation at the Y705 site without affecting the total STAT3 protein level, and suppresses the IL-6/JAK/STAT3 pathway. STAT3-IN-53 downregulates the transcription and expression of cyclin-D1 and c-Myc. STAT3-IN-53 induces cell cycle arrest and promotes Apoptosis. STAT3-IN-53 exhibits anticancer activity against colorectal cancer .
STAT3-IN-51 is a STAT3 inhibitor that directly binds to the STAT3 SH2 domain. STAT3-IN-51 induces apoptosis, ferroptosis, and immunogenic cell death (ICD) to potentiate anti-tumor immunity. STAT3-IN-51 inhibits STAT3 activation (phosphorylation, p-STAT3) and its downstream signaling. STAT3-IN-51 induces ROS generation, decreases Bcl-2 expression, disruptes mitochondrial function, suppresses GPX4 activity, and promotes lipid peroxidation. STAT3-IN-51 can be used for the study of colorectal carcinoma, breast adenocarcinoma, non-small cell lung cancer (NSCLC) and Cisplatin (HY-17394)-resistant pulmonary adenocarcinoma .
H2N-PEG3400-SH (Amine-PEG3400-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG3400-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG20000-SH (Amine-PEG20000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG20000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG40000-SH (Amine-PEG40000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG40000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG5000-SH (Amine-PEG5000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG5000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
Thiol-PEG2-NH2 (SH-PEG2-NH2) is a PEG derivative consisting of a thiol (-SH), 2 PEG units, and NH2. Thiol is a highly reactive chemical group that can react specifically with a variety of molecules to form stable covalent bonds.
Bt354 is an orally active STAT3 inhibitor with IC50 values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis, and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer, prostate cancer and neuropathic pain [2] .
H2N-PEG1000-SH (Amine-PEG1000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG1000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG10000-SH (Amine-PEG10000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG10000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG2000-SH (Amine-PEG2000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG2000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG3400-SH (Amine-PEG3400-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG3400-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG20000-SH (Amine-PEG20000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG20000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG40000-SH (Amine-PEG40000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG40000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
H2N-PEG5000-SH (Amine-PEG5000-Thiol) hydrochloride is a linear heterobifunctional PEGylated product containing thiol and amine. H2N-PEG5000-SH hydrochloride is an important cross-linking or bioconjugation reagent with PEG chains. Thiol or SH, sulfhydryl or thiol selectively reacts with maleimide, OPSS, vinyl sulfone and transition metal surfaces (including gold, silver, etc.) .
Thiol-PEG2-NH2 (SH-PEG2-NH2) is a PEG derivative consisting of a thiol (-SH), 2 PEG units, and NH2. Thiol is a highly reactive chemical group that can react specifically with a variety of molecules to form stable covalent bonds.
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains [2].
Grb2SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
Grb2SH2 domain inhibitor 1 is an inhibitor of the Grb2SH2 domain with an IC50 of 0.40 μM. Grb2SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2SH2 domain inhibitor 1 downregulates the expression level of p-MEK. Grb2SH2 domain inhibitor 1 can be used in the research of breast cancer .
pYEEI is a phosphotyrosine-containing tetrapeptide binds to Src SH2 domain with the Kd of 100 nM and with the IC50 of 6.5 μM. pYEEI plays an important role in cancer research .
G7-18NATE TFA is a peptide inhibitor of Grb7. G7-18NATE TFA binds to the Grb7-SH2 domain with micromolar affinity (Kd = 18.1 μM). G7-18NATE TFA inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
IRS1-derived peptide is a biological active peptide. (This is a peptide fragment (979-989) of the insulin receptor substrate-1 containing the sequence motif YMXM known to bind to the two domains of SH2 on the 85kDa subunit of phosphoinositide 3-kinase.)
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide and has STAT3 inhibitory activity. 5-FAM-GpYLPQTV-NH2 (TFA) can be used in cancer research .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions .
G7-18NATE is a peptide inhibitor of Grb7. HY-P10224 binds to the Grb7-SH2 domain with micromolar affinity (KD = 18.1 μM). G7-18NATE inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
FITC-Acp-RpYTPEP-NH2 is a potent fluorescent tracer. FITC-Acp-RpYTPEP-NH2 shows a binding affinity (Kd = 0.07 μM) for the Cbl-bSH2 domain. Fluorescence polarization assay based on FITC-Acp-RpYTPEP-NH2 can be for evaluating Cbl-b SH2 domain inhibitors .
Isocryptotanshinone is a dual STAT3 and PTP1B (IC50 = 56.1 μM) inhibitor. Isocryptotanshinone inhibits STAT3 by binding to the STAT3 SH2 domain to block phosphorylation and nuclear translocation [1][2]. Isocryptotanshinone exerts its anti-proliferative effect via the induction of cell cycle arrest, apoptosis, and pro-death autophagy, through the regulation of STAT3, AKT/mTOR and MAPK signaling pathways. Isocryptotanshinone suppresses the xenograft gastric cancer (GC) tumor growth in BALB/c nude mice. Isocryptotanshinone can be used for cancer research, such as lung cancer, breast cancer and GC .
SH2D1A protein regulates receptors of the SLAM family (SLAMF1, CD244, LY9, CD84, SLAMF6, and SLAMF7). SH2D1A Protein, Human (His) is the recombinant human-derived SH2D1A protein, expressed by E. coli , with N-6*His labeled tag.
The SLP-76 protein is critical in T cell antigen receptor-mediated signaling and participates in multiple molecular interactions. Its association with SLA coordinates T cell signaling, whereas its interaction with CBLB emphasizes regulatory effects. SLP-76 Protein, Human (His-T7) is the recombinant human-derived SLP-76 protein, expressed by E. coli , with N-T7, C-6*His labeled tag.
CISH 1; CISH1; Cytokine inducible SH2 protein 1; JAB; JAK binding protein; JAK-binding protein; Janus kinase binding protein ; SOCS 1; TEC interacting protein 3; Tec-interacting protein 3; TIP 3
The SOCS1 protein is an important negative regulator that inhibits type I and type II interferon signaling as well as cytokines such as IL2, IL4, IL6, and LIF. It downregulates the signaling of the JAK/STAT pathway by inhibiting JAK proteins and IFNGR1. SOCS1 Protein, Human (P.pastoris, His) is the recombinant human-derived SOCS1 protein, expressed by P. pastoris , with N-His labeled tag.
NCK1 protein is an adapter protein that binds to tyrosine phosphorylated receptors (KDR, PDGFRB) and cellular substrates and plays a key role in the dephosphorylation of EIF2S1 by PP1. It contributes to the efficient activation of DNA damage response effector (CHEK2) and ELK1-dependent transcriptional activation in Ras signaling. NCK1 Protein, Human (His) is the recombinant human-derived NCK1 protein, expressed by E. coli , with N-6*His labeled tag.
Grb2, an adapter protein, crucially connects cell surface growth factor receptors to the Ras signaling pathway. Despite no direct binding to phosphorylated EGFR, Grb2 inhibits EGF-induced transactivation of a RAS-responsive element. It acts as a dominant negative relative to GRB2, suppressing proliferative signals and potentially initiating programmed cell death. Grb2 Protein, Human (His) is the recombinant human-derived Grb2 protein, expressed by E. coli , with C-6*His labeled tag.
SHC1; SHC; SHCA; SHC-transforming protein 1; SHC-transforming protein 3; SHC-transforming protein A; Src homology 2 domain-containing-transforming protein C1; SH2 domain protein C1
WB, IHC-P, ICC/IF, FC
Human, Mouse, Rat
SHC Antibody (YA2394) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SHC.
CD307b, FCRH2, IFGP4, IRTA4, SPAP1, UNQ9236/PRO31998, FCRL2, Fc receptor-like protein 2, FcR-like protein 2, FcRL2, Fc receptor homolog 2, IFGP family protein 4, Immunoglobulin receptor translocation-associated protein 4, SH2 domain-containing phosphatase anchor protein 1, FcRH2
FC, ELISA
Human
FCRL2/CD307B Antibody (YA7121) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to FCRL2/CD307B.
SD-36 is a potent and efficacious STAT3 PROTAC degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase . SD-36 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
SH2B2 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2b3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sh2b3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2b3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sh2b3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B3 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2d1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sh2d1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2d1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Sh2d1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D2A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D4A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D3C Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D3C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1B Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
